Lipigon Pharmaceuticals Valuation
| LPGO Stock | SEK 0.17 0.03 15.00% |
Lipigon Pharmaceuticals seems to be overvalued based on Macroaxis valuation methodology. Our model forecasts the value of Lipigon Pharmaceuticals from analyzing the firm fundamentals such as Operating Margin of (338.33) %, return on equity of -1.7, and Shares Outstanding of 20.24 M as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that Lipigon Pharmaceuticals' price fluctuation is out of control at this time. Calculation of the real value of Lipigon Pharmaceuticals is based on 3 months time horizon. Increasing Lipigon Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Lipigon Pharmaceuticals' intrinsic value may or may not be the same as its current market price of 0.17, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.17 | Real 0.16 | Hype 0.17 | Naive 0.18 |
The intrinsic value of Lipigon Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lipigon Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lipigon Pharmaceuticals AB helps investors to forecast how Lipigon stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lipigon Pharmaceuticals more accurately as focusing exclusively on Lipigon Pharmaceuticals' fundamentals will not take into account other important factors: Lipigon Pharmaceuticals Total Value Analysis
Lipigon Pharmaceuticals AB is now anticipated to have takeover price of 5.58 M with market capitalization of 25.81 M, debt of , and cash on hands of 58.95 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Lipigon Pharmaceuticals fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.58 M | 25.81 M | 58.95 M |
Lipigon Pharmaceuticals Investor Information
About 38.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.62. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lipigon Pharmaceuticals recorded a loss per share of 4.65. The entity had not issued any dividends in recent years. Based on the key indicators related to Lipigon Pharmaceuticals' liquidity, profitability, solvency, and operating efficiencyBased on the analysis of, Lipigon Pharmaceuticals AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.Lipigon Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lipigon Pharmaceuticals has an asset utilization ratio of 10.81 percent. This implies that the Company is making kr0.11 for each dollar of assets. An increasing asset utilization means that Lipigon Pharmaceuticals AB is more efficient with each dollar of assets it utilizes for everyday operations.Lipigon Pharmaceuticals Ownership Allocation
Lipigon Pharmaceuticals maintains a total of 20.24 Million outstanding shares. Lipigon Pharmaceuticals AB holds significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lipigon Pharmaceuticals Profitability Analysis
The company reported the revenue of 3.18 M. Net Loss for the year was (41.11 M) with loss before overhead, payroll, taxes, and interest of (36.04 M).About Lipigon Pharmaceuticals Valuation
The stock valuation mechanism determines Lipigon Pharmaceuticals' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Lipigon Pharmaceuticals based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Lipigon Pharmaceuticals. We calculate exposure to Lipigon Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lipigon Pharmaceuticals's related companies.Lipigon Pharmaceuticals AB develops drugs for lipid related diseases in Sweden. Lipigon Pharmaceuticals AB was founded in 2010 and is based in Ume, Sweden. Lipigon Pharmaceuticals is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct Lipigon Pharmaceuticals' Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Lipigon Pharmaceuticals' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Lipigon Pharmaceuticals' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Lipigon Pharmaceuticals' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Lipigon Pharmaceuticals' revenue streams: Identify Lipigon Pharmaceuticals' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Lipigon Pharmaceuticals' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Lipigon Pharmaceuticals' growth potential: Evaluate Lipigon Pharmaceuticals' management, business model, and growth potential.
- Determine Lipigon Pharmaceuticals' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Lipigon Pharmaceuticals' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for Lipigon Stock Analysis
When running Lipigon Pharmaceuticals' price analysis, check to measure Lipigon Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipigon Pharmaceuticals is operating at the current time. Most of Lipigon Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Lipigon Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipigon Pharmaceuticals' price. Additionally, you may evaluate how the addition of Lipigon Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.